Utilization of appetite suppressants in England: A putative indicator of poor prescribing practice

Pharmacoepidemiology and Drug Safety

Volumn 5, Issue 4, 1996, Pages 237-246

  Thomas, S H L ^a   Campbell, M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Appetite depressants; Drug utilization; Quality of health care

Indexed keywords

AMFEPRAMONE; ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; PHENTERMINE; PHENTERMINE RESIN;

ARTICLE; DRUG USE; HUMAN; OBESITY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0029786944     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199607)5:4<237::AID-PDS218>3.0.CO;2-X     Document Type: Article

References (15)

1. Miach, P. J., Thompson, W. M., Doyle, A. E. and Louis, W. J. Double-blind crossover evaluation of mazindol in the treatment of obese hypertensive patients. Medical Journal of Australia 1976; 2: 378-380.
2. Atkinson, R. E., Greenway, F. L., Bray, G., et al. Treatment of obesity: comparison of medical and non physician therapists using placebo and anorectic drugs in a double-blind study. International Journal of Obesity 1977; 1: 113-121.
3. Douglas, J. G., Gough, J., Preston, P. G., et al. Long-term efficacy of fenfluramine in treatment of obesity. Lancet 1983; i: 384-386.
4. Weintraub, M., Hasday, J. D., Mushlin, A. I. and Lockwood, D. H. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Archives of Internal Medicine 1984; 144: 1143-1148.
5. Goodall, E., Oxtoby, C., Richards, R., Watkinson, G., Brown, D. and Silverstone, T. A. Clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of obesity. British Journal of Psychiatry 1988; 153: 208-213.
6. Guy-Grand, B., Apfelbaum, M., Crepaldi, G., Gries, A., Lefebvre, P. and Turner, P. International trial of long-term dexfenfluramine on obesity. Lancet 1989; ii: 1142-1144.
7. Weintraub, M., Sundaresan, P. R., Madan, M., et al. Long-term weight control: the National Heart Lung and Blood Institute funded multimodal intervention study. Long-term weight control study I (weeks 0-34). Clinical Pharmacology and Therapeutics 1992; 51: 586-594.
8. Weintraub, M., Sundaresan, P. R., Schuster, B., Averbuch, M., Stein, C. and Byrne, L. Long-term weight control: the National Heart Lung and Blood Institute funded multimodal intervention study. Long-term weight control study V (weeks 190-210). Follow-up of participants after cessation of medication. Clinical Pharmacology and Therapeutics 1992; 51: 615-618.
9. British Medical Association, London and The Pharmaceutical Press, Royal Pharmaceutical Society of Great Britain, London. British National Formulary September 1991; No. 22.
10. Douglas, J. G., Munro, J. F., Kitchen, A. H., Muir, A. L. and Proudfoot, A. T. Pulmonary hypertension and fenfluramine. British Medical Journal 1981; 223: 881-883.
11. McMurray, J., Bloomfield, P. and Miller, H. C. Irreversible pulmonary hypertension after treatment with fenfluramine. British Medical Journal 1986; 292: 239-240.
12. Pouwels, H. M. M., Smeets, J. L. R. M., Cheriex, E. C. and Wouters, E. F. M. Pulmonary hypertension and fenfluramine. European Respiratory Journal 1990; 3: 606-607.
13. Roche, N., Labrune, S., Braun, J.-M. and Huchon, G. J. Pulmonary hypertension and dexfenfluramine. Lancet 1992; i: 436-437.
14. Committee on Safety of Medicines. Fenfluramine (Ponderax pacaps), dexfenfluramine (Adifax) and pulmonary hypertension. Current Problems 1992; No. 34.
15. Campbell, M., Kennedy, J., Bateman, N., Smith, J. and Thomas, S. Cerebral and peripheral vasodilators - markers of poor prescribing quality (abstract). Pharmacoepidemiology and Drug Safety 1994; 3 (Suppl 1): pS85 (single page).